ストックスクリーナーアプリを入手
1.62
5.19%
0.08
アフターアワーズ：
1.64
0.02
+1.23%
前日終値:
$1.54
開ける：
$1.56
24時間の取引高:
441.40K
Relative Volume:
0.37
時価総額：
$97.52M
収益：
-
当期純損益:
$-73.79M
株価収益率:
-0.8804
EPS:
-1.84
ネットキャッシュフロー:
$-77.44M
1週間 パフォーマンス:
-1.22%
1か月 パフォーマンス:
+3.85%
6か月 パフォーマンス:
-57.92%
1年 パフォーマンス:
-59.80%
1日の値動き範囲:
$1.56
$1.66
1週間の範囲:
$1.5005
$1.67
52週間の値動き範囲:
$1.39
$6.85
Pyxis Oncology Inc Stock (PYXS) Company Profile
PYXS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
1.62 | 97.52M | 0 | -73.79M | -77.44M | -1.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-21 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-11-08 | 開始されました | Stephens | Overweight |
| 2024-08-08 | 開始されました | Stifel | Buy |
| 2024-05-07 | 再開されました | Jefferies | Buy |
| 2024-02-09 | 開始されました | BTIG Research | Buy |
| 2024-01-23 | 開始されました | Leerink Partners | Outperform |
| 2023-09-05 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-11-02 | 開始されました | BofA Securities | Neutral |
| 2021-11-02 | 開始されました | Credit Suisse | Outperform |
| 2021-11-02 | 開始されました | Jefferies | Buy |
すべてを表示
Pyxis Oncology Inc (PYXS) 最新ニュース
Pyxis Oncology plummets 38% on preliminary phase 1 data for cancer asset - MSN
Barclays PLC Purchases 46,997 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Pyxis Oncology, Inc. (NASDAQ:PYXS) Holdings Raised by Jane Street Group LLC - Defense World
Pyxis Oncology stock hits 52-week low at $1.49 By Investing.com - Investing.com South Africa
Pyxis Oncology stock hits 52-week low at $1.49 - Investing.com India
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $9.43 Average Price Target from Analysts - MarketBeat
Pyxis Oncology, Inc. (NASDAQ:PYXS) Stock Position Raised by Geode Capital Management LLC - Defense World
Barclays PLC Increases Stock Position in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
State Street Corp Buys 208,344 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Pick Pyxis in head and neck despite pullback on ADC phase I? - BioWorld Online
Pyxis Oncology stock outlook adjusted with focus on ADC program and cost management - Investing.com Nigeria
Pyxis Oncology stock outlook adjusted with focus on ADC program and cost management By Investing.com - Investing.com South Africa
Pyxis Oncology’s (PYXS) “Outperform” Rating Reiterated at Royal Bank of Canada - Defense World
Pyxis Oncology price target lowered to $8 from $10 at RBC Capital - Yahoo Finance
Pyxis Oncology shares target cut, outperform rating on pipeline update By Investing.com - Investing.com Australia
Pyxis Oncology shares target cut, outperform rating on pipeline update - Investing.com
Pyxis Oncology's (PYXS) Buy Rating Reiterated at HC Wainwright - MarketBeat
Pyxis Oncology's Deprioritizes Second Pipeline Asset, Analyst Applauds Move - Benzinga
Royal Bank of Canada Reaffirms Outperform Rating for Pyxis Oncology (NASDAQ:PYXS) - MarketBeat
Pyxis Oncology advances lead cancer drug PYX-201 By Investing.com - Investing.com Canada
Pyxis Oncology to Focus on PYX-201, Suspends PYX-106 Program - MarketWatch
Pyxis Oncology advances lead cancer drug PYX-201 - Investing.com
Pyxis Oncology to prioritize PYX-201, suspends investment in PYX-106 - TipRanks
Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201 - The Manila Times
Pyxis Oncology, Inc. Announces Portfolio Prioritization, Focusing Resources on Its Lead Clinical Program, PYX-201 - Marketscreener.com
Pyxis Oncology stock hits 52-week low at $1.5 amid market challenges - Investing.com Canada
Pyxis Oncology's SWOT analysis: ADC developer's stock shows promise amid trials - Investing.com Canada
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $10.00 Average Price Target from Brokerages - MarketBeat
Pyxis Oncology stock hits 52-week low at $1.64 - Investing.com
Pyxis Oncology stock hits 52-week low at $1.64 By Investing.com - Investing.com UK
Jacobs Levy Equity Management Inc. Makes New Investment in Pyxis Oncology, Inc. (NASDAQ:PYXS) - MarketBeat
14,897 Shares in Pyxis Oncology, Inc. (NASDAQ:PYXS) Bought by Intech Investment Management LLC - Defense World
Pyxis Oncology: Speculative Buy Opportunity With Multiple Catalysts Ahead (NASDAQ:PYXS) - Seeking Alpha
CFO & COO of Pyxis Oncology Pamela Connealy Buys 13% More Shares - Yahoo Finance
Pyxis Oncology CFO acquires shares worth $174,364 - Investing.com India
Pyxis Oncology CFO acquires shares worth $174,364 By Investing.com - Investing.com South Africa
Institutional owners may ignore Pyxis Oncology, Inc.'s (NASDAQ:PYXS) recent US$142m market cap decline as longer-term profits stay in the green - Yahoo Finance
Pressure on Pyxis despite promising PYX-201 data - The Pharma Letter
Pyxis Oncology's SWOT analysis: ADC innovator's stock poised for growth - Investing.com
Pyxis Oncology's SWOT analysis: ADC innovator's stock poised for growth By Investing.com - Investing.com UK
Pyxis Oncology Inc (PYXS) 財務データ
収益
当期純利益
現金流量
EPS
5.49%
0.79%
大文字化:
|
ボリューム (24 時間):